Selective LOXL2 inhibition: Potent antifibrotic effects in ongoing fibrosis and fibrosis regression

Gut

Volumn 66, Issue 9, 2017, Pages 1540-1541

  Magdaleno, Fernando ^a,b   Trebicka, Jonel ^a,c,d  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d European Foundation for the Study of Chronic Liver Failure (EF CLIF)   (Spain)

Author keywords

Extracellular Matrix; Fibrosis; Liver Cirrhosis

Indexed keywords

AB 0023; ALPHAVBETA6 INTEGRIN; COLLAGEN; COPPER PROTEIN; FOCAL ADHESION KINASE; GELATINASE B; LYSYL OXIDASE LIKE PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; PROTEIN KINASE B; PROTEIN LYSINE 6 OXIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

CELL ADHESION; CELL DEATH; CELL PROLIFERATION; CROSS LINKING; ENZYME ACTIVITY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELL; HUMAN; INTRACELLULAR SIGNALING; LIVER FIBROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REMISSION; SHORT SURVEY; FIBROSIS; LIVER CIRRHOSIS;

FIBROSIS; HUMANS; LIVER CIRRHOSIS;

EID: 85020279856     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-313621     Document Type: Short Survey

References (10)

1. Ikenaga N, Peng ZW, Vaid KA, et al. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut 2017;66:1697-708.
2. Schierwagen R, Leeming DJ, Klein S, et al. Serum markers of the extracellular matrix remodeling reflect antifibrotic therapy in bile-duct ligated rats. Front Physiol 2013;4:195.
3. Leeming DJ, Anadol E, Schierwagen R, et al. Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. AIDS 2014;28:2081-90.
4. Kim BR, Dong SM, Seo SH, et al. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1. Cell Signal 2014;26:1765-73.
5. Mederacke I, Hsu CC, Troeger JS, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun 2013;4:2823.
6. Herranz N, Dave N, Millanes-Romero A, et al. Lysyl oxidase-like 2 deaminates lysine 4 in histone H3. Mol Cell 2012;46:369-76.
7. Popov Y, Patsenker E, Stickel F, et al. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies. J Hepatol 2008;48:453-64.
8. Vadasz Z, Kessler O, Akiri G, et al. Abnormal deposition of collagen around hepatocytes in Wilson's disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2. J Hepatol 2005;43:499-507.
9. Yang J, Savvatis K, Kang JS, et al. Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment. Nat Commun 2016;7:13710.
10. Raghu G, Brown KK, Collard HR, et al. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: A randomised, doubleblind, controlled, phase 2 trial. Lancet Respir Med 2017;5:22-32.